Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma

Parvin F. Peddi, May Cho, Jian Wang, Feng Gao, Andrea Wang-Gillam

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

Background: The standard of care in patients with metastatic pancreatic adenocarcinoma is undefined beyond second line of treatment. There have been scant reports of benefit from nab-paclitaxel in patients with refractory pancreatic cancer. Materials and methods: A retrospective review was carried out in patients with pancreatic adenocarcinoma at Siteman Cancer Center, who had received nab-paclitaxel monotherapy after experiencing disease progression on standard treatments. Nab-paclitaxel was given either two out of every three weeks or three out of every four weeks. Results: Twenty patients were identified and included for data analysis. Median age was 63.5 years old. All patients had previously received gemcitabine, while 40% had also received FOLFIRINOX. Median number of prior lines of systemic treatment was 2. Patients were treated for a median of 15 weeks, with a range of 1 to 41.7 weeks. Median dose of nab-paclitaxel was 100 mg/m2 with range of 75-125 mg/m2. Best response imaging was available in 17 patients and 11 out of the 17 patients (64.7%) had stable disease. Median progression-free survival (PFS) was 3.7 months and overall survival (OS) were 5.2 months. Most common treatment related toxicities included grade 1 pneumonitis in five patients (25%), grade 3 or 4 neutropenia in three patients (15%), and dehydration resulting in hospitalization in one patient (5%). Conclusions: Nab-paclitaxel monotherapy had acceptable level of toxicity in a heavily pretreated patient population with pancreatic cancer and appeared to provide a clinical benefit. This agent is worthy of further prospective studies to evaluate extent of benefit after standard therapies have failed.

Original languageEnglish (US)
Pages (from-to)370-373
Number of pages4
JournalJournal of Gastrointestinal Oncology
Volume4
Issue number4
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

    Fingerprint

Keywords

  • Monotherapy
  • Nab-paclitaxel
  • Pancreatic adenocarcinoma
  • Refractory disease
  • Registry study

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this